Marker Therapeutics, Inc.

Marker ended Q1 2021 with $64.5 million in cash and cash equivalents, following a $56.5 million public offering of common stock. Net loss was $8.8 million versus $6.5 million in the prior-year quarter. R&D expense was $5.6 million versus $3.8 million a year ago, and G&A expense was $3.1 million versus $2.8 million a year ago. Management said current cash should support operations into the first quarter of 2023. For forward progress, the company expects to complete the six-patient safety lead-in mid-year and open the main portion of the Phase II AML study, with first patient treatment in the main protocol anticipated in Q3. They plan about 120 patients in the adjuvant randomized portion and about 40 patients in the active-disease single-arm portion, but no revenue guidance was provided.

Peter Hoang framed the quarter as an important operational start to the year, centered on advancing MT-401 in AML and preparing manufacturing in-house. He emphasized that the company is focused on translating its multi-antigen T-cell approach into a potentially transformative therapy for a patient population with poor survival outcomes. His tone was optimistic but still execution-focused, repeatedly stressing enrollment, manufacturing readiness, and site expansion.

Tony Kim highlighted the financing and balance sheet first: $64.5 million in cash and cash equivalents at quarter end, with runway into Q1 2023. He also reported the quarter’s net loss of $8.8 million, R&D spending of $5.6 million, and G&A of $3.1 million. The increase in R&D was mainly due to higher headcount and infrastructure costs tied to growth in research and development operations; he did not discuss capital allocation beyond funding operations.

Analysts focused on what the six-patient safety lead-in would show, whether any disclosures would follow, and whether the company might raise dose levels in the main Phase II study. Management said the primary endpoint is dose-limiting toxicities, that they expect to finish the safety lead-in mid-year, and that the new manufacturing process could allow higher doses; they also noted Baylor data has already explored higher doses and found them safe. Questions also centered on manufacturing comparability and next indications, where management said the FDA comparability work is already settled, the new process has better analytical and biological characteristics, and future indications such as pancreatic cancer remain under consideration but AML is the current focus.